BRCA1 and ovarian cancer: Recently reported results have revealed that after 3 years since the ovarian cancer diagnosis, the presence of a BRCA1 or BRCA2 mutation was associated with a clinically better prognosis (HR 0.68; 95 % CI: 0.48–0.98, p = 0.03), which has not been sustained 10 years after the diagnosis of ovarian cancer (HR 1.00; 95 % CI: 0.83–1.22, p = 0.90) [16, 17].